Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5932730 | 0.95 | ALDH1A1 (0.39) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL4795603 | 0.90 | ALDH1A1 (0.39) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL2190588 | 0.89 | — | — | |
| SCHEMBL20547673 | 0.89 | ALDH1A1 (0.43) | THRBALDH1A1TSHR | |
| SCHEMBL5932497 | 0.87 | THRB (0.39) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL29150457 | 0.87 | THRB (0.39) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL12924146 | 0.87 | THRB (0.52) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL12924144 | 0.87 | THRB (0.52) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL5319244 | 0.85 | HTT (0.60) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL5933467 | 0.84 | ALDH1A1 (0.39) | THRBMEN1HTTKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11850237-B2 | Compounds and methods for treating influenza | ROMARK LABORATORIES L.C. (US) | 2023-12-26 | — | — | US | disclosed |
| EP-2445349-B1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES LC (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3895706-A1 | THIAZOLINIDE COMPOUNDS FOR TREATING NON-INFLUENZA VIRAL INFECTIONS | Romark Laboratories, L.C. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20210177809-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES L.C. (US) | 2021-06-17 | — | — | US | disclosed |
| US-10912768-B2 | Compounds and methods for treating influenza | ROMARK LABORATORIES L.C. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10577337-B2 | Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof | ROMARK LABORATORIES, L.C. (US) | 2020-03-03 | — | — | US | disclosed |
| US-RE47786-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES L.C. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190307730-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES L.C. (US) | 2019-10-10 | — | — | US | disclosed |
| US-20190276417-A1 | COMPOSITIONS AND METHODS OF TREATMENT WITH PRODRUGS OF TIZOXANIDE, AN ANALOGUE OR SALT THEREOF | ROMARK LABORATORIES, L.C. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10363243-B2 | Compounds and methods for treating influenza | ROMARK LABORATORIES L.C. (US) | 2019-07-30 | — | — | US | disclosed |
| WO-2007008529-A2 | CELULLAR CHOLESTEROL ABSORPTION MODIFIERS | KALYPSYS, INC (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006124874-A2 | INHIBITORS OF B-RAF KINASE | KALYPSYS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006124780-A2 | IH-BENZO [D] IMIDAZOLE COMPOUNDS AS INHIBITORS OF B-RAF KINASE | KALYPSYS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006116355-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060205736-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060167012-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC. | 2006-07-27 | — | — | US | disclosed |
| WO-2006060424-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | KALYPSYS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
| WO-2006055187-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | THRB 1246/4885MEN1 4731/4885HTT 4845/4885 |
| US-20060167012-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | PPARG, PPARA, PPARD | THRB 228/4885MEN1 4811/4885HTT 1602/4885 |
| US-10912768-B2 | Compounds and methods for treating influenza | HIF1AN, HAVCR2, NEU1 | THRB 3392/4885MEN1 3237/4885HTT 3110/4885 |
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | THRB 1088/4885MEN1 3740/4885HTT 2882/4885 |
| US-20210177809-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | HIF1AN, HAVCR2, NEU1 | THRB 3392/4885MEN1 3237/4885HTT 3110/4885 |
| US-20190307730-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | HIF1AN, HAVCR2, NEU1 | THRB 3392/4885MEN1 3237/4885HTT 3110/4885 |
| US-11850237-B2 | Compounds and methods for treating influenza | HIF1AN, HAVCR2, NEU1 | THRB 3392/4885MEN1 3237/4885HTT 3110/4885 |
| US-20190276417-A1 | COMPOSITIONS AND METHODS OF TREATMENT WITH PRODRUGS OF TIZOXANIDE, AN ANALOGUE OR SALT THEREOF | TK1, SLC7A1, SI | THRB 2183/4885MEN1 2641/4885HTT 4125/4885 |
| US-10577337-B2 | Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof | TK1, SLC7A1, SI | THRB 2183/4885MEN1 2641/4885HTT 4125/4885 |
| US-10363243-B2 | Compounds and methods for treating influenza | HIF1AN, HAVCR2, NEU1 | THRB 3392/4885MEN1 3237/4885HTT 3110/4885 |
| US-20060205736-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | PPARG, PPARA, PPARD | THRB 228/4885MEN1 4811/4885HTT 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.